Bron Luc, Romero Pedro
Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, CHUV, 1011 Lausanne.
Rev Med Suisse. 2006 Oct 4;2(81):2216-9.
In the past decades, prognosis of head and neck squamous cell carcinoma (HNSCC) has not improved despite substantial progress in treatment options. Since antitumoral immunity was described, immunotherapy has shown promising results as an adjunctive treatment in various cancer types. Tumor-associated antigens (TAAs) have been identified and shown to stimulate selective T-cell-mediated antitumoral immune response. This article briefly reviews the work done in the field of immunotherapy of HNSCC in the past few years. It gives confidence that immunotherapy may play an important role in the treatment of head and neck squamous cell carcinoma. Among various TAAs, the family of cancer testis antigens (CTAs) may be promising candidates for specific immune therapy in HNSCC. Ongoing studies will confirm whether CTAs may generate an immune response in clinical vaccine trials.
在过去几十年里，尽管头颈部鳞状细胞癌（HNSCC）的治疗方案取得了重大进展，但其预后并未得到改善。自从抗肿瘤免疫被描述以来，免疫疗法作为一种辅助治疗方法在各种癌症类型中都显示出了有前景的结果。肿瘤相关抗原（TAA）已被识别并显示能刺激选择性T细胞介导的抗肿瘤免疫反应。本文简要回顾了过去几年在HNSCC免疫治疗领域所做的工作。这让人相信免疫疗法可能在头颈部鳞状细胞癌的治疗中发挥重要作用。在各种TAA中，癌胚抗原（CTA）家族可能是HNSCC特异性免疫治疗的有前景的候选者。正在进行的研究将证实CTA在临床疫苗试验中是否能产生免疫反应。
